BiotechTube
Home/Tectonic Therapeutic/Anthony Muslin
AM

Anthony Muslin

Chief Development Officer

Tectonic Therapeutic

Therapeutic Areas

CardiopulmonaryFibrotic Diseases

Tectonic Therapeutic Pipeline

DrugIndicationPhase
TX000045 (TX45)Heart Failure with Preserved Ejection Fraction (HFpEF) / Group 2 Pulmonary HypertensionPhase 1
Relaxin ProgramGroup 2 Pulmonary HypertensionPreclinical
Undisclosed ProgramHereditary Hemorrhagic Telangiectasia (HHT)Discovery

Leadership Team at Tectonic Therapeutic

AR
Alise Reicin
President and CEO, Director
JD
John Diener
Senior Vice President, Antibody Engineering & Protein Sciences
DL
Daniel Lochner
Chief Financial Officer
PM
Peter McNamara
Chief Scientific Officer
MK
Marcella K Ruddy
Chief Medical Officer
MS
Marc Schwabish
Chief Business Officer
GP
Geraldine Peters-Wiles
Senior Vice President, Human Resources
BR
Barry Rubenstein
Senior Vice President, People & Culture
TA
Timothy A. Springer
Co-Founder, Board Director
AC
Andrew C. Kruse
Co-Founder
View full Tectonic Therapeutic profile